<DOC>
	<DOCNO>NCT00001068</DOCNO>
	<brief_summary>To determine influence virus load , CD4 count , biologic phenotype , presence symptomatic disease response HIV-infected patient new therapeutic regimen . PER AMENDMENT 8/27/96 : To extend availability currently assign ACTG 303 treatment 6 month .</brief_summary>
	<brief_title>A Study Disease Progression Anti-HIV Treatments</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion Criteria Patients must : Prior participation protocol ACTG 175 . PER AMENDMENT 8/27/96 : Patients must study/on treatment time protocol study treatment extend .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Zalcitabine</keyword>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Lamivudine</keyword>
</DOC>